Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
50 hedge funds and large institutions have $4.38M invested in Clearside Biomedical in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 18 reducing their positions, and 17 closing their positions.
0.33% less ownership
Funds ownership: 1.13% → 0.8% (-0.33%)
12% less funds holding
Funds holding: 57 → 50 (-7)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
30% less call options, than puts
Call options by funds: $67K | Put options by funds: $96K
48% less capital invested
Capital invested by funds: $8.46M → $4.38M (-$4.08M)
67% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$588K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$441K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$150K |
| 4 |
Goldman Sachs
New York
|
+$145K |
| 5 |
Jane Street
New York
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.51M |
| 2 |
State Street
Boston,
Massachusetts
|
-$554K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$538K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$125K |
| 5 |
VF
Virtu Financial
New York
|
-$95K |
CLSD Hedge Fund Activity: Q2 2019 in Review
50 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2019, worth a combined $4.38M — down 48% from $8.46M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CLSD and 12 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 6 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $588K. The largest seller was BlackRock, cutting an estimated $1.51M.
- 50 institutional investors held Clearside Biomedical (CLSD) as of Q2 2019, down from 57 in Q1 2019.
- Funds reported $4.38M of Clearside Biomedical stock for Q2 2019, down 48% quarter-over-quarter.
- 12 funds opened new Clearside Biomedical positions in Q2 2019 and 17 closed out, a net change of -5 holders.
- The largest Clearside Biomedical buyer in Q2 2019 was Millennium Management, an estimated $588K added.
- The largest Clearside Biomedical seller in Q2 2019 was BlackRock, an estimated $1.51M sold.
Based on aggregated 13F filings for Q2 2019.